Welcome to our dedicated page for Artelo Biosciences news (Ticker: ARTL), a resource for investors and traders seeking the latest updates and insights on Artelo Biosciences stock.
Overview of Artelo Biosciences Inc (ARTL)
Artelo Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapeutics. With a strong focus on lipid-signaling pathways and the endocannabinoid system, the company employs a disciplined approach to leverage decades of research and cutting‐edge science. Its innovative platform is designed to modulate complex biochemical networks, aiming to address significant unmet medical needs in conditions such as cancer, pain, anxiety, anorexia, and inflammation.
Core Business and Product Portfolio
At its core, Artelo Biosciences targets lipid-mediated signaling mechanisms to develop proprietary therapies that have the potential to transform patient care. The company’s research spans several therapeutic areas, including:
- Cannabinoid-based Therapeutics: Utilizing a proprietary cocrystal composition that combines cannabidiol (CBD) with tetramethylpyrazine (TMP), the company is innovating in the realm of cannabinoid pharmacology. Their flagship product candidate exhibits superior pharmacokinetic and pharmacodynamic properties compared to conventional CBD formulations.
- FABP Inhibitors: A highlight of the portfolio is the selective inhibition of Fatty Acid Binding Protein 5 (FABP5), an approach designed to provide non-opioid, non-steroidal pain management solutions. These inhibitors are being explored in various pain models including chemotherapy-induced peripheral neuropathy, cancer bone pain, and osteoarthritis-related discomfort.
- Appetite and Cachexia Management: Artelo is developing therapies aimed at supporting patients suffering from cancer-related anorexia. Their efforts focus on improving body weight, appetite, and overall quality of life by targeting specific G-Protein Coupled Receptors (GPCRs) linked to metabolic regulation.
Scientific Innovation and Research Excellence
Artelo Biosciences emphasizes scientific innovation and regulatory discipline. The company strategically leverages world-class research expertise in its collaborations across Europe and North America. This collaborative approach ensures that the preclinical and clinical development of their compounds is built on robust scientific findings. Utilizing advanced drug formulation techniques such as cocrystallization, the company addresses challenges related to solubility and bioavailability, thereby optimizing the delivery and efficacy of their compounds.
Operational Footprint and Global Presence
Headquartered in San Diego, California, and with a significant presence in Dublin, Ireland, Artelo Biosciences has strategically positioned itself at the nexus of global biopharmaceutical innovation. This dual presence facilitates access to premier research institutions and allows the company to foster partnerships with leading academic and commercial entities across both the North American and European markets.
Competitive Position and Industry Significance
In the competitive landscape of clinical-stage biopharmaceutical companies, Artelo Biosciences distinguishes itself through its specialized focus on lipid-signaling and endocannabinoid modulation. By capitalizing on novel mechanisms of action and proprietary technologies, the company aims to fill clinical gaps where existing therapies are inadequate. Its methodical approach to product candidate development, emphasizing improved pharmacological profiles and optimized formulations, positions it as a credible player in the market. In a world where precision medicine and targeted therapies are increasingly important, Artelo’s platform presents a relevant and enduring solution for diverse therapeutic challenges.
Expertise, Experience, and Collaborative Strength
The leadership at Artelo Biosciences is composed of experienced biopharmaceutical executives and renowned researchers with deep domain expertise. This seasoned team guides the company’s multi-disciplinary projects, ensuring that every phase of development integrates regulatory excellence and scientific rigor. Strategic collaborations with academic institutions and industry partners enhance the company’s pipeline by providing access to innovative methodologies and specialized research tools, thus reinforcing its commitment to high-impact therapeutic discoveries.
Research and Development Strategy
Artelo’s R&D strategy is driven by an integrated approach that spans early discovery to clinical development. Each product candidate is supported by extensive preclinical validation, demonstrating efficacy in well-established laboratory models of disease. The company’s emphasis on establishing patent-protected products further underscores its commitment to long-term innovation. Through an agile development process, Artelo continuously refines its drug candidates to enhance safety, dosing precision, and clinical applicability. This systematic approach highlights the company’s regulatory discipline and forward-thinking in addressing complex pathologies.
Addressing Unmet Medical Needs
The challenges in treating conditions such as chemotherapeutic pain, chronic neuropathies, and cancer-associated cachexia underscore a significant need for innovative therapeutic options. Artelo Biosciences’ approach, which modulates upstream lipid-signaling pathways, offers the potential to achieve clinical benefits not attainable with traditional therapies. By focusing on molecular targets that regulate bioactive lipids, the company promises solutions that are less reliant on conventional mechanisms, thereby reducing adverse effects while improving efficacy.
Scientific Integrity and Transparency
In its commitment to scientific integrity and transparency, Artelo Biosciences provides comprehensive disclosure on its research methods and collaborative engagements. The company’s numerous presentations at global scientific symposia demonstrate its dedication to contributing to the broader body of knowledge in cannabinoid research and lipid signaling. This openness reinforces its reputation for expertise and builds trust among stakeholders, including investors, researchers, and clinical practitioners.
Conclusion
Artelo Biosciences Inc is a dynamic and forward-thinking biopharmaceutical company that has built a niche in the development of novel therapies targeting lipid-signaling pathways. With a robust and diversified drug pipeline, a strong scientific foundation, and a global operational footprint, the company continues to contribute valuable insights and therapeutic solutions in areas where patient needs are greatest. By maintaining a clear focus on rigorous research and strategic collaborations, Artelo is well-equipped to sustain its relevance and impact in the evolving landscape of biopharmaceutical innovation.
Artelo Biosciences (ARTL) announced the receipt of Clinical Trials Authorization for its Cancer Appetite Recovery Study (CAReS) of ART27.13 in the UK. This Phase I/II trial targets cancer patients suffering from anorexia, addressing a significant unmet medical need. The company also secured a Mitacs Accelerate grant to further develop its ART26.12 program, exploring its potential in treating anxiety disorders. Financially, ARTL reported a net loss of $1.43 million for Q1 FY2021, with operating expenses slightly rising to $1.44 million.
Artelo Biosciences (NASDAQ: ARTL) announced its participation in the H.C. Wainwright BioConnect 2021 Conference, scheduled for January 11-14, 2021. The presentation will be available on-demand starting January 11 at 6:00 a.m. EDT and accessible for 90 days. Artelo is focused on developing therapeutics that modulate the endocannabinoid system to address unmet medical needs in conditions such as cancer, PTSD, and pain. The company is based in San Diego and is advancing a portfolio of product candidates aimed at various diseases.
Artelo Biosciences (NASDAQ: ARTL) has filed a composition of matter patent application with the UK Patent Office for a new solid dosage formulation related to its lead clinical program, ART27.13. This formulation aims to treat cancer patients suffering from anorexia. The company has received Clinical Trial Authorization for its Cancer Appetite Recovery Study (CAReS) and plans to begin enrollment by year-end 2020. If allowed, the patent application is expected to secure exclusivity for ART27.13 through 2041.
Artelo Biosciences (NASDAQ: ARTL) announced its participation in the 13th Annual LD Micro Main Event investor conference on December 15 at 9:40 a.m. PST. Gregory D. Gorgas, President and CEO, will present to a live virtual audience. The conference format includes a 10-minute presentation followed by a Q&A session. The Main Event takes place on December 14-15 on the Sequire Virtual Events platform. Artelo is focused on developing therapeutics targeting the endocannabinoid system, addressing unmet medical needs in various conditions such as cancer and pain.
Artelo Biosciences (NASDAQ: ARTL) announced the appointment of Gregory R. Reyes, M.D., Ph.D., to its Board of Directors, effective November 30, 2020. Dr. Reyes brings over 35 years of experience in biotech and pharmaceuticals, having advanced over 50 drug candidates in his career. He previously held significant positions at Celgene, Biogen Idec, Pfizer, and Schering-Plough, contributing to the development of successful therapeutics like Merck’s Victrelis. Artelo aims to leverage Dr. Reyes' expertise to enhance its clinical development and product pipeline.
Artelo Biosciences (NASDAQ: ARTL) announced a Mitacs Accelerate grant that will fund 50% of research costs for evaluating ART26.12 as a potential treatment for anxiety disorders. The grant supports preclinical research in collaboration with Dr. Steven Laviolette at the University of Western Ontario. ART26.12 aims to inhibit Fatty Acid Binding Protein 5 (FABP5), potentially increasing anandamide levels, which may enhance treatment efficacy for anxiety. The funding will also aid in pharmacology research and biomarker identification related to stress response.
Artelo Biosciences (NASDAQ: ARTL) has received Clinical Trial Authorization (CTA) in the UK for its Cancer Appetite Recovery Study (CAReS) aimed at treating cancer-related anorexia. The Phase 1/2 trial will evaluate the efficacy and safety of synthetic cannabinoid ART27.13, targeting a market of over $2 billion. With a recruitment goal of 43 patients, the company plans to initiate enrollment before year-end 2020, despite operational challenges posed by the Covid-19 pandemic. The trial addresses a significant unmet need, as cancer-related anorexia affects over 60% of advanced cancer patients.
Artelo Biosciences (NASDAQ:ARTL), a biopharmaceutical company, will present at the Virtual Fall Investor Summit from November 16-18, 2020. CEO Gregory D. Gorgas is scheduled to speak on November 18 at 11:30 a.m. ET. The presentation will be available for live streaming and replay. Attendees can schedule one-on-one meetings via video calls during the summit. Artelo focuses on developing therapeutics targeting the endocannabinoid system for conditions like anorexia, cancer, and pain. For details, visit www.artelobio.com.
Artelo Biosciences (NASDAQ: ARTL) recently announced the closing of a $7.6 million underwritten public offering and received ethics approval for the CAReS study of ART27.13 in the UK. The company expanded its exclusive worldwide license with Stony Brook University for the FABP5 inhibitor platform aimed at treating cancer, pain, and inflammation. For the fiscal year ending August 31, 2020, Artelo reported a net loss of $4.65 million or $1.26 per share, an increase from the previous year, and had cash reserves of approximately $2.14 million.
Artelo Biosciences (NASDAQ: ARTL) has announced a significant advance in the treatment of psychological disorders, filing a patent for FABP5 inhibitors aimed at conditions like anxiety and PTSD. Recent preclinical data indicate that inhibiting FABP5 increases anandamide levels in critical brain regions, potentially providing a new therapeutic pathway with fewer side effects compared to current treatments. This is particularly relevant as COVID-19 may heighten PTSD risks. The company has also expanded its patent estate by acquiring rights to third-generation FABP5 inhibitors.
FAQ
What is the current stock price of Artelo Biosciences (ARTL)?
What is the market cap of Artelo Biosciences (ARTL)?
What is the primary focus of Artelo Biosciences?
What types of therapies is Artelo developing?
How does Artelo Biosciences differentiate itself in the biopharmaceutical industry?
Where is Artelo Biosciences headquartered?
What is the significance of the company’s proprietary cocrystal technology?
What conditions are targeted by Artelo’s FABP inhibitors?
How does Artelo Biosciences support its research and development efforts?
Is Artelo focused on addressing unmet medical needs?
